[What is reliable in the therapy of hematologic diseases? II. Anemias, myeloproliferative diseases, panmyelopathy and agranulocytosis].
D000361:Agammaglobulinemia / Q000628:therapy; D000380:Agranulocytosis / Q000188:drug therapy*; D000740:Anemia / Q000188:drug therapy* / Q000235:genetics; D000743:Anemia, Hemolytic / Q000628:therapy; D000747:Anemia, Hypochromic / Q000188:drug therapy; D000748:Anemia, Macrocytic / Q000188:drug therapy; D000756:Anemia, Sideroblastic / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000628:therapy*; D004612:Elliptocytosis, Hereditary / Q000628:therapy; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D005494:Folic Acid Deficiency / Q000188:drug therapy; D006801:Humans; D007501:Iron / Q000008:administration & dosage; D009196:Myeloproliferative Disorders / Q000188:drug therapy*; D011087:Polycythemia Vera / Q000209:etiology; D011247:Pregnancy; D055728:Primary Myelofibrosis / Q000628:therapy; D013103:Spherocytosis, Hereditary / Q000628:therapy; D013789:Thalassemia / Q000628:therapy; D014805:Vitamin B 12 / Q000627:therapeutic use; D014806:Vitamin B 12 Deficiency / Q000188:drug therapy
D000970:Antineoplastic Agents; D005492:Folic Acid; D007501:Iron; D014805:Vitamin B 12
Was ist gesichert in der Therapie der hämatologischen Erkrankungen? II. Anämien, myeloproliferative Erkrankungen, Panmyelopathie und Agranulocytose.